ME01090B - Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat - Google Patents
Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidratInfo
- Publication number
- ME01090B ME01090B MEP-2009-338A MEP33809A ME01090B ME 01090 B ME01090 B ME 01090B ME P33809 A MEP33809 A ME P33809A ME 01090 B ME01090 B ME 01090B
- Authority
- ME
- Montenegro
- Prior art keywords
- hemihydrate
- disorder
- compound according
- composition
- disorders
- Prior art date
Links
- ITIHHRMYZPNGRC-QRPNPIFTSA-N lorcaserin hydrochloride Chemical compound Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12 ITIHHRMYZPNGRC-QRPNPIFTSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract 7
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010022773 Intracranial pressure increased Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010029216 Nervousness Diseases 0.000 claims 2
- 208000027626 Neurocognitive disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 201000010064 diabetes insipidus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 201000000484 premenstrual tension Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63822104P | 2004-12-21 | 2004-12-21 | |
| EP05855526A EP1838677B1 (en) | 2004-12-21 | 2005-12-20 | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| PCT/US2005/046983 WO2006069363A2 (en) | 2004-12-21 | 2005-12-20 | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01090B true ME01090B (me) | 2012-12-20 |
Family
ID=36602366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-338A ME01090B (me) | 2004-12-21 | 2005-12-20 | Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8168624B2 (https=) |
| EP (3) | EP2327698B1 (https=) |
| JP (3) | JP5270167B2 (https=) |
| KR (1) | KR101281919B1 (https=) |
| CN (2) | CN101084193B (https=) |
| AT (1) | ATE442359T1 (https=) |
| AU (1) | AU2005318959B2 (https=) |
| BR (1) | BRPI0519726B8 (https=) |
| CA (1) | CA2589988C (https=) |
| CU (1) | CU20070138A7 (https=) |
| CY (1) | CY1109599T1 (https=) |
| DE (1) | DE602005016603D1 (https=) |
| DK (1) | DK1838677T3 (https=) |
| EA (2) | EA201200954A1 (https=) |
| ES (1) | ES2332009T3 (https=) |
| HR (1) | HRP20090640T1 (https=) |
| IL (1) | IL183844A (https=) |
| MA (1) | MA29147B1 (https=) |
| ME (1) | ME01090B (https=) |
| NI (1) | NI200700160A (https=) |
| NZ (2) | NZ555981A (https=) |
| PL (1) | PL1838677T3 (https=) |
| PT (1) | PT1838677E (https=) |
| RS (1) | RS50996B (https=) |
| SI (1) | SI1838677T1 (https=) |
| TN (1) | TNSN07235A1 (https=) |
| WO (1) | WO2006069363A2 (https=) |
| ZA (1) | ZA200705125B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| PL2332921T3 (pl) * | 2003-06-17 | 2016-08-31 | Arena Pharm Inc | Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny |
| CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| NZ555981A (en) | 2004-12-21 | 2011-01-28 | Arena Pharm Inc | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| BRPI0515862A2 (pt) | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
| AU2006287202B2 (en) | 2005-09-01 | 2013-01-24 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists |
| CN101253153A (zh) | 2005-09-01 | 2008-08-27 | 伊莱利利公司 | 作为5－HT<sub>2c</sub>受体激动剂的6－取代的2,3,4,5－四氢－1H－苯并[d]氮杂䓬 |
| ATE438627T1 (de) | 2005-09-01 | 2009-08-15 | Lilly Co Eli | 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten |
| CA2619450C (en) | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| EP2001852A2 (en) * | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| CN101547892B (zh) * | 2006-12-05 | 2014-08-20 | 艾尼纳制药公司 | 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体 |
| EP2288585A1 (en) | 2008-03-04 | 2011-03-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
| US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| AU2011296015B2 (en) | 2010-09-01 | 2015-11-12 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| JP6272695B2 (ja) * | 2010-09-01 | 2018-01-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| KR20130138770A (ko) * | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| AU2015268758B2 (en) * | 2010-09-01 | 2017-08-24 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2c agonists useful for weight management |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| AU2011296027A1 (en) * | 2010-09-01 | 2013-04-04 | Arena Pharmaceuticals, Inc. | Fast-dissolve dosage forms of 5-HT2C agonists |
| JP2013536859A (ja) * | 2010-09-01 | 2013-09-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストの非吸湿性塩 |
| JP2015534563A (ja) | 2012-10-09 | 2015-12-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 体重管理の方法 |
| EP2868656A1 (en) | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Stabilized amorphous lorcaserin hydrochloride |
| US9714225B2 (en) * | 2013-11-13 | 2017-07-25 | Cadila Healthcare Limited | Processes for the preparation of lorcaserin |
| WO2015096119A1 (zh) * | 2013-12-27 | 2015-07-02 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| EP2924024A3 (en) | 2014-03-21 | 2016-01-20 | Medichem, S.A. | Solid forms of lorcaserin hydrochloride |
| US9981912B2 (en) | 2014-04-21 | 2018-05-29 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof |
| WO2015170346A1 (en) | 2014-05-09 | 2015-11-12 | Council Of Scientific & Industrial Research | A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers |
| TW201618787A (zh) | 2014-10-30 | 2016-06-01 | 艾尼納製藥公司 | 組合物及方法 |
| CN104844512B (zh) * | 2015-05-15 | 2017-03-29 | 东北制药集团股份有限公司 | 一种绿卡色林盐酸盐半水合物晶型的制备方法 |
| CN104829532A (zh) * | 2015-05-15 | 2015-08-12 | 浙江理工大学 | 一种制备绿卡色林盐酸盐单晶的方法 |
| HK1245079A1 (zh) * | 2015-06-30 | 2018-08-24 | 纽拉德有限公司 | 新颖呼吸控制调节化合物以及其制备和使用方法 |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913990RA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| EP3210975A1 (en) | 2016-02-24 | 2017-08-30 | Enantia, S.L. | Cocrystals of lorcaserin |
| CN106478506B (zh) * | 2016-09-30 | 2019-03-15 | 山东科兴生物制品有限公司 | 半水绿卡色林盐酸盐的制备方法 |
| CN112704670B (zh) * | 2021-01-08 | 2022-07-15 | 安徽中医药大学 | 一种盐酸氯卡色林渗透泵控释制剂及其制备方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
| CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
| CA974989A (en) | 1968-03-11 | 1975-09-23 | Wallace And Tiernan Inc. | Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby |
| US4233217A (en) | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
| FR7736M (https=) | 1968-09-02 | 1970-03-09 | ||
| US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
| US3795683A (en) | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
| LU65954A1 (https=) | 1972-08-25 | 1974-03-07 | ||
| US4210749A (en) | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
| US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4108989A (en) | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
| CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
| AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| DE3272044D1 (de) | 1981-11-27 | 1986-08-21 | Smithkline Beckman Corp | 3-benzazepines as alpha-2 antagonists |
| FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
| US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
| US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US4762845A (en) | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| US5015639A (en) | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
| ZA882080B (en) | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
| AU1700688A (en) | 1987-04-09 | 1988-11-04 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
| US5422355A (en) | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
| US5178786A (en) | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
| AU8201591A (en) | 1990-06-15 | 1992-01-07 | Schering Corporation | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them |
| US5275915A (en) | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
| WO1993000094A2 (en) | 1991-06-21 | 1993-01-07 | Smithkline Beecham Plc | Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine |
| EP0558824A1 (en) | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof |
| JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
| JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
| ZA944513B (en) | 1993-06-23 | 1996-01-16 | Cambridge Neuroscience Inc | Sigma receptor ligands |
| US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| DE4419315A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419246A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419247A1 (de) | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
| DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
| JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
| CA2190708A1 (en) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
| US5925651A (en) | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| WO1998006701A1 (en) | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
| EP0987235B1 (en) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| ES2209728T3 (es) | 1999-08-06 | 2004-07-01 | F. Hoffmann-La Roche Ag | Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico. |
| DE10003708A1 (de) | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
| EP1335915B1 (en) | 2000-11-14 | 2008-01-02 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| WO2002074746A1 (en) | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Benzazepine derivatives |
| DE10119278C1 (de) | 2001-04-20 | 2002-10-02 | Merck Patent Gmbh | Verfahren zur Herstellung von Fluoralkylphosphaten |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AU2002356525A1 (en) | 2001-09-24 | 2003-04-07 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| PL2332921T3 (pl) * | 2003-06-17 | 2016-08-31 | Arena Pharm Inc | Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny |
| CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| US20080009478A1 (en) | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| WO2005042490A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| JP2008508348A (ja) | 2004-08-02 | 2008-03-21 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 銅含有アミンオキシダーゼを阻害するための化合物およびその使用 |
| US8178077B2 (en) | 2004-10-19 | 2012-05-15 | Reverse Proteomics Research Institute Co., Ltd. | Drug development target protein and target gene, and method of screening |
| NZ555981A (en) | 2004-12-21 | 2011-01-28 | Arena Pharm Inc | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| BRPI0515862A2 (pt) | 2004-12-23 | 2011-10-11 | Arena Pharm Inc | uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas |
| EP2001852A2 (en) | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| JP5339263B2 (ja) | 2007-07-26 | 2013-11-13 | コクヨ株式会社 | 引き戸の取付構造、引き戸及び収納装置 |
-
2005
- 2005-12-20 NZ NZ555981A patent/NZ555981A/en not_active IP Right Cessation
- 2005-12-20 US US11/793,473 patent/US8168624B2/en active Active
- 2005-12-20 PL PL05855526T patent/PL1838677T3/pl unknown
- 2005-12-20 EP EP10010048.6A patent/EP2327698B1/en not_active Expired - Lifetime
- 2005-12-20 HR HR20090640T patent/HRP20090640T1/hr unknown
- 2005-12-20 JP JP2007547060A patent/JP5270167B2/ja not_active Expired - Fee Related
- 2005-12-20 AT AT05855526T patent/ATE442359T1/de active
- 2005-12-20 RS RSP-2009/0476A patent/RS50996B/sr unknown
- 2005-12-20 NZ NZ589756A patent/NZ589756A/en not_active IP Right Cessation
- 2005-12-20 ES ES05855526T patent/ES2332009T3/es not_active Expired - Lifetime
- 2005-12-20 DE DE602005016603T patent/DE602005016603D1/de not_active Expired - Lifetime
- 2005-12-20 BR BRPI0519726A patent/BRPI0519726B8/pt active IP Right Grant
- 2005-12-20 CN CN2005800433929A patent/CN101084193B/zh not_active Expired - Lifetime
- 2005-12-20 PT PT05855526T patent/PT1838677E/pt unknown
- 2005-12-20 DK DK05855526T patent/DK1838677T3/da active
- 2005-12-20 SI SI200530839T patent/SI1838677T1/sl unknown
- 2005-12-20 ME MEP-2009-338A patent/ME01090B/me unknown
- 2005-12-20 CN CN2011103046342A patent/CN102321023A/zh active Pending
- 2005-12-20 EA EA201200954A patent/EA201200954A1/ru unknown
- 2005-12-20 CA CA2589988A patent/CA2589988C/en not_active Expired - Lifetime
- 2005-12-20 WO PCT/US2005/046983 patent/WO2006069363A2/en not_active Ceased
- 2005-12-20 AU AU2005318959A patent/AU2005318959B2/en not_active Expired
- 2005-12-20 KR KR1020077016727A patent/KR101281919B1/ko not_active Expired - Fee Related
- 2005-12-20 EP EP09011453A patent/EP2149562A1/en not_active Withdrawn
- 2005-12-20 EP EP05855526A patent/EP1838677B1/en not_active Expired - Lifetime
- 2005-12-20 EA EA200701358A patent/EA017894B1/ru unknown
-
2007
- 2007-06-11 IL IL183844A patent/IL183844A/en active IP Right Grant
- 2007-06-15 CU CU20070138A patent/CU20070138A7/es unknown
- 2007-06-20 ZA ZA2007/05125A patent/ZA200705125B/en unknown
- 2007-06-20 TN TNP2007000235A patent/TNSN07235A1/fr unknown
- 2007-06-21 NI NI200700160A patent/NI200700160A/es unknown
- 2007-07-12 MA MA30070A patent/MA29147B1/fr unknown
-
2009
- 2009-11-10 CY CY20091101162T patent/CY1109599T1/el unknown
-
2012
- 2012-03-21 US US13/425,669 patent/US8697686B2/en not_active Expired - Lifetime
- 2012-05-18 JP JP2012114460A patent/JP5781008B2/ja not_active Expired - Fee Related
- 2012-09-14 US US13/616,887 patent/US8980881B2/en not_active Expired - Lifetime
-
2014
- 2014-06-02 JP JP2014113743A patent/JP2014156490A/ja active Pending
-
2015
- 2015-03-02 US US14/635,146 patent/US20160009654A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01090B (me) | Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat | |
| JP2008524262A5 (https=) | ||
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| MX2009013742A (es) | 2-imidazolinas. | |
| WO2011057973A9 (en) | Oxazoline derivatives for treatment of cns disorders | |
| MY162160A (en) | Pyrazole derivatives | |
| FI3252057T3 (fi) | Multisyklisiä yhdisteitä ja niiden käyttömenetelmiä | |
| CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
| JP2013512926A5 (https=) | ||
| EA201100748A1 (ru) | Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10 | |
| ATE516586T1 (de) | Neue intermetallische verbindungen, ihre verwendung und herstellungsverfahren dafür | |
| RU2012153918A (ru) | Жевательная резинка с комбинацией физиологических охладителей и способ ее изготовления | |
| MX351918B (es) | Derivados heterociclicos de amina. | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| JP2008044931A5 (https=) | ||
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| MX2015001108A (es) | Derivados de triazol carboxamida. | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| NO20091936L (no) | 4-imidazoliner som TAAR ligander | |
| MX2009013745A (es) | 4-imidazolinas y su uso como antidepresivos. | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| JP2008526706A5 (https=) | ||
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| RU2012153379A (ru) | Способ получения неопентилгликоля | |
| WO2008058867A3 (en) | Substituted 4-imidazoles |